0000000000224776

AUTHOR

Jan C. Simon

showing 4 related works from this author

Thy-1 (CD90) regulates the extravasation of leukocytes during inflammation.

2010

Human Thy-1 (CD90) has been shown to mediate adhesion of inflammatory cells to activated microvascular endothelial cells via interaction with Mac-1 (CD11b/CD18) in vitro. Since there are no data showing the physiological relevance of Thy-1 for the recruitment of inflammatory cells in vivo, different inflammation models were investigated in Thy-1-deficient mice and littermate controls. In thioglycollate-induced peritonitis, the number of neutrophils and monocytes was significantly diminished in Thy-1-deficient mice. During acute lung inflammation, the extravasation of eosinophils and monocytes into the lung was significantly reduced in Thy-1-deficient mice. Moreover, during chronic lung infl…

ChemokineMice 129 StrainNeutrophilsmedicine.medical_treatmentT-LymphocytesImmunologyInflammationCD18In Vitro TechniquesPeritonitisMonocytesMiceCell MovementCell AdhesionLeukocytesImmunology and AllergyMedicineAnimalsHumansCD90Thy-1InflammationMice KnockoutTransplantation Chimerabiologybusiness.industryInterleukinsEndothelial CellsPneumoniaExtravasationTransplantationEosinophilsMice Inbred C57BLCytokineIntegrin alpha MImmunologybiology.proteinThy-1 Antigensmedicine.symptomChemokinesbusinessextravasationPeptide HydrolasesEuropean journal of immunology
researchProduct

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase

2011

Background A subgroup of patients with chronic spontaneous urticaria (CU) exhibits IgE antibodies directed against autoantigens, such as thyroperoxidase (TPO). We conducted this study to investigate whether such patients with CU with IgE against TPO benefit from treatment with omalizumab, a humanized anti-IgE mAb licensed for the treatment of severe persistent allergic (IgE-mediated) asthma. Objectives We sought to assess the efficacy of omalizumab treatment in patients with CU with IgE autoantibodies against TPO. Methods In this multicenter, randomized, double-blind, placebo-controlled study patients with CU (male/female, 18-70 years of age) with IgE autoantibodies against TPO who had pers…

AdultMalemedicine.medical_specialtyAdolescentUrticariamedicine.medical_treatmentImmunologyOmalizumabOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboAutoantigensGastroenterologylaw.inventionYoung AdultRandomized controlled triallawInternal medicineAnti-Allergic AgentsmedicineHumansImmunology and AllergyAdverse effectAgedAutoantibodiesAsthmabiologybusiness.industryAntibodies MonoclonalImmunoglobulin EMiddle Agedmedicine.diseaseAntibodies Anti-IdiotypicTolerabilityImmunologybiology.proteinFemaleAntihistaminebusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Photobiologie und klinische Immunologie (V 66–V 70)

2000

medicine.medical_specialtyOtorhinolaryngologybusiness.industryImmunology and AllergyMedicinebusinessDermatologyAllergo Journal
researchProduct

Kontaktallergie (V 58–V 65)

2000

medicine.medical_specialtyOtorhinolaryngologybusiness.industrymedicineImmunology and AllergybusinessDermatologyAllergo Journal
researchProduct